



HBeAg-Positive
PegINF alfa-2a versus Lamivudine versus Both

PegINF alfa-2a versus Lamivudine versus Both HBeAg-Positive Patients: Study Design



PegINF alfa-2a versus Lamivudine versus Both HBeAg-Positive Patients: Results

HBeAg-POSITIVE Patients: Week 72 Treatment Response



PegINF alfa-2a versus Lamivudine versus Both HBeAg-Positive Patients: Conclusions

Conclusions: “In patients with HBeAg-positive chronic hepatitis B, peginterferon alfa-2a offers superior efficacy over lamivudine, on the basis of HBeAg seroconversion, HBV DNA suppression, and HBsAg seroconversion.”